Skip to content

BEYOND Weight Loss Study

Body Composition and Energy Expenditure With Total Diet Replacement During Weight Loss and Maintenance

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02340793
Acronym
BEYOND
Enrollment
23
Registered
2015-01-19
Start date
2015-01-31
Completion date
2017-02-28
Last updated
2018-01-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity

Keywords

Weight loss

Brief summary

National guidelines recommend 15-20% weight loss for severe and complicated obesity. Weight loss maintenance can be achieved in around 33% of patients at 12 months. The BEYOND study will administer Counterweight Plus; a nutritionally replete Total Diet Replacement Plan (TDR) of 800+ Calories followed by structured Food Reintroduction, and Weight Loss Maintenance programmes. The study will incorporate three work packages with the aim of: 1. examining changes in body composition with substantial (target \>15kg) non-surgical weight loss (work package 1, WP1) 2. characterizing the metabolic adaptations during weight loss and maintenance (work package 2, WP2) 3. examining Rescue Packages as a method of weight re-gain prevention (work package 3, WP3).

Detailed description

All participants will receive the Counterweight Plus dietary intervention. This consists of: * 12-20 weeks 800+ calories/day Total Diet Replacement Plan, followed by * 6-8 weeks Food Reintroduction, followed by * up to 104 weeks Weight Loss Maintenance, based on maintaining daily calorie restriction. All participants will undergo the following investigations at baseline and at regular intervals throughout the study period: * height (baseline only) * whole body MRI scans: total-body skeletal muscle volume and fat mass will be measured using whole-body multi-slice MRI (baseline and 12 weeks only) * functional assessment: completion of the Western Ontario and McMaster Universities Arthritis Index (WOMAC) (baseline and 12 weeks only) * gait and muscle strength assessment: biomechanical gait analysis will be carried out using an 8 camera VICON system during flat walking to determine maximum flexion and extension moments for both limbs and maximum adduction and abduction moments. Muscle strength will also be directly measured of both the upper (grip strength) and lower (quadriceps and hamstrings) limb using a dynamometer and myometer (baseline and 12 weeks only) * anthropometric measurement: body weight; waist, hip, thigh, arm and calf circumferences * indirect calorimetry: resting metabolic rate will be measured by a computerised open-circuit ventilated hood system * fasting blood sampling: for measurement of HbA1C, lipid profile, leptin, thyroid hormones * gut microbiota analysis from faecal samples * Binge Eating Disorder and Quality of Life (EQ-5D) questionnaires Participants will receive regular support/advice from a research dietician/ nutritionist during the two year study period.

Interventions

DIETARY_SUPPLEMENTCounterweight Plus

A non-surgical, nutritionally replete weight management programme comprising a Total Diet Replacement Plan (TDR) of 800+ calories/day to produce a weight loss of \>15kg over 12-20 weeks; followed by a structured Food Reintroduction phase for 6-8 weeks and a Weight Loss Maintenance phase; total intervention period 2 years.

Sponsors

University of Glasgow
CollaboratorOTHER
NHS Greater Glasgow and Clyde
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* confirmation from general practitioner (GP) of suitability for intervention * written informed consent * female * BMI ≥30 kg/m2 and \< 45kg/m2, weight\<200 kg and \<60 cm bore size

Exclusion criteria

* known illness such as heart disease, cancer, or any disability that would affect weight loss (diabetes not an exclusion) or prevent completion of the intervention * implanted electronic devices that are MRI incompatible or MRI unsafe, ferromagnetic foreign bodies * substance abuse * myocardial infarction within previous 6 months * learning difficulties and subjects having difficulty in understanding verbal or written English * pregnant/ considering pregnancy * patients who have required hospitalisation for depression or are on antipsychotic drugs * people currently participating in another clinical research trial * recent weight loss \>5kg within the last 6 months * current treatment with anti-obesity drugs * diagnosed eating disorder

Design outcomes

Primary

MeasureTime frameDescription
WP1: change in body composition with substantial, non-surgical, weight loss20 weeksMeasurement of muscle mass before and after a weight loss programme using MRI
WP2: metabolic adaptation during weight loss and maintenance2 yearsChange in resting metabolic rate before and after weight loss
WP3: weight regain prevention2 years% achieving \>15kg weight loss at 12 and 24 months

Secondary

MeasureTime frameDescription
Muscle/fat mass of specific muscle groups20 weeksRelationship between predicted muscle and fat mass with the strength of specific muscle groups (by muscle strength, gait analysis and WOMAC questionnaire)
Weight regain prevention2 yearschanges in BED Questionnaire Rating Score
Adherence and acceptability of Rescue Packages to Patients2 yearsNumber of participants requiring and completing rescue packages
Metabolic adaptive effect of weight loss2 yearsComparison of leptin, ghrelin and thyroid hormone levels at baseline to those during weight loss and maintenance to establish

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026